Table_2_SERPINB3 Delays Glomerulonephritis and Attenuates the Lupus-Like Disease in Lupus Murine Models by Inducing a More Tolerogenic Immune Phenotype.DOCX by Mariele Gatto (444286)

“…<p>Objective: To explore the effects of SERPINB3 administration in murine lupus models with a focus on lupus-like nephritis.</p><p>Methods: 40 NZB/W F1 mice were subdivided into 4 groups and intraperitoneally injected with recombinant SERPINB3 (7.5 μg/0.1 mL or 15 μg/0.1 mL) or PBS (0.1 mL) before (group 1 and 2) or after (group 3 and 4) the development of proteinuria (≥100 mg/dl). …”

DataSheet1_Evaluation of the COVID-19 vaccine effectiveness on the outcomes of COVID 19 disease in Iran: a test-negative case-control study.pdf by Fatemeh Khosravi Shadmani (6335432)

“…</p>Methods<p>This study is a test-negative case-control design using data from eight provinces in April, 2021 until March, 2022. …”

Image_2_Tyrosine-Protein Phosphatase Non-receptor Type 9 (PTPN9) Negatively Regulates the Paracrine Vasoprotective Activity of Bone-Marrow Derived Pro-angiogenic Cells: Impact on V... by Michel Desjarlais (6832442)

“…Background and Aim<p>Insufficient post-ischemic neovascularization is an initial key step in the pathogenesis of Oxygen-Induced Retinopathy (OIR). …”

Probability of localization in 93.5 dB re 1 <i>μ</i>Pa root median square noise. by Regina A. Guazzo (4543420)

“…In the 50th percentile noise conditions, the probability of localization within the area of the array was approximately 100%. Probability of localization increases as noise levels decrease. …”

Table_1_Associations among past trauma, post-displacement stressors, and mental health outcomes in Rohingya refugees in Bangladesh: A secondary cross-sectional analysis.pdf by Haley Ritsema (14431125)

“…Trauma (OR = 4.98, 95% CI = 2.20–11.31, p < 0.001) was associated with increased odds of PTSD. Living in a household that received income was associated with decreased odds of PTSD (OR = 0.74, 95% CI = 0.55–1.00, p = 0.05).…”

Image4_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.JPEG by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Image6_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.JPEG by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Image3_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.JPEG by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Table2_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.DOCX by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Image1_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.JPEG by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Table4_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.docx by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Image2_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.JPEG by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Image7_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.JPEG by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Image5_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.JPEG by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Table3_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.docx by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Table1_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.docx by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

The mediating effect of body mass index on the relationship between smoking and hip or knee replacement due to primary osteoarthritis. A population-based cohort study (the HUNT Stu... by Marianne Bakke Johnsen (4723974)

“…We identified 1322 THRs and 754 TKRs. For men, the total effect of current vs. never smoking revealed a decreased risk of THR (HR 0.59, 95% CI 0.46–0.76) and TKR (HR 0.47, 95% CI 0.32–0.66). …”

Data Sheet 3_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.xlsx by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

A hypothesis-driven <i>in vitro</i> genetic screen of <i>S</i>. <i>aureus</i> mutants to identify genes required for propagation through nanopores. by Elysia A. Masters (9553742)

“…WT USA300 is plotted as the positive control (grey bar) and mutant pools are indicated by colors matching panel A. Of the 24 mutants screened, only <i>agrC</i>, <i>sasC</i> and <i>pbp4</i> displayed a significantly decreased propagation efficiency compared to 100% propagation efficiency of WT USA300 <i>S</i>. …”

Data Sheet 1_Comparison of percutaneous vs. cutdown access for endovascular aortic repair in the treatment of type B aortic dissection: a meta-analysis.pdf by Zhongyou Liang (22617608)

“…In comparison to CEVAR, PEVAR resulted in a reduced hospital length of stay (MD = −2.16 days, 95% CI: −3.05 to −1.27, P < 0.00001), decreased operative time (MD = −40.87 min, 95% CI: −49.72 to −32.02, P < 0.00001), shorter postoperative duration (MD = −1.01 days, 95% CI: −1.56 to −0.45, P = 0.0004), diminished incidence of groin infection (OR = 0.44, 95% CI: 0.30 to 0.65, P < 0.0001), lower occurrence of heart-related complications (OR = 0.76, 95% CI: 0.59 to 1.00, P = 0.05), and reduced incidence of lymphocele (OR = 0.49, 95% CI: 0.24 to 0.98, P = 0.04), but a higher incidence of surgical suture failure (OR = 2.61, 95% CI: 1.52 to 4.50, P = 0.0005) and pseudoaneurysm (OR = 2.64, 95% CI: 1.09 to 6.41, P = 0.03). …”